Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Huys

Showing results (1-10 of 206) with videos related to

Pageof 21
Sort By:
Frontiers in Medicine|November 12, 2021
R&D Costs of New Medicines: A Landscape AnalysisSteven Simoens, Isabelle Huys
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Emerging Insights into European Markets of Biologics, Including BiosimilarsSteven Simoens, Isabelle Huys
The European Journal of Neuroscience|May 20, 2003
Evidence for a function-specific mutation in the neurotoxin, parabutoxin 3Isabelle Huys, Jan Tytgat
Frontiers in Medicine|December 23, 2017
Innovative Approaches to Increase Access to Medicines in Developing CountriesHilde Stevens, Isabelle Huys
Drug Discovery Today|December 5, 2021
How much do the public sector and the private sector contribute to biopharmaceutical R&D?Steven Simoens, Isabelle Huys
Seminars in Thrombosis and Hemostasis|December 14, 2012
Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challengesSteven Simoens, Isabelle Huys
Trials|May 5, 2021
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical researchCiska Verbaanderd, Ilse Rooman, Isabelle Huys
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|March 18, 2004
Structure-function study of a chlorotoxin-chimer and its activity on Kv1.3 channelsIsabelle Huys, Etienne Waelkens, Jan Tytgat
Frontiers in Genetics|October 21, 2022
The future regulation of artificial intelligence systems in healthcare services and medical research in the European UnionJanos Meszaros, Jusaku Minari, Isabelle Huys
Targeted Oncology|January 18, 2012
Biosimilars and market access: a question of comparability and costs?Steven Simoens, Gilbert Verbeken, Isabelle Huys
Pageof 21

Showing results (1-10 of 206) with videos related to

Sort By:
Pageof 21
Frontiers in Medicine|November 12, 2021
R&D Costs of New Medicines: A Landscape AnalysisSteven Simoens, Isabelle Huys
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Emerging Insights into European Markets of Biologics, Including BiosimilarsSteven Simoens, Isabelle Huys
The European Journal of Neuroscience|May 20, 2003
Evidence for a function-specific mutation in the neurotoxin, parabutoxin 3Isabelle Huys, Jan Tytgat
Frontiers in Medicine|December 23, 2017
Innovative Approaches to Increase Access to Medicines in Developing CountriesHilde Stevens, Isabelle Huys
Drug Discovery Today|December 5, 2021
How much do the public sector and the private sector contribute to biopharmaceutical R&D?Steven Simoens, Isabelle Huys
Seminars in Thrombosis and Hemostasis|December 14, 2012
Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challengesSteven Simoens, Isabelle Huys
Trials|May 5, 2021
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical researchCiska Verbaanderd, Ilse Rooman, Isabelle Huys
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|March 18, 2004
Structure-function study of a chlorotoxin-chimer and its activity on Kv1.3 channelsIsabelle Huys, Etienne Waelkens, Jan Tytgat
Frontiers in Genetics|October 21, 2022
The future regulation of artificial intelligence systems in healthcare services and medical research in the European UnionJanos Meszaros, Jusaku Minari, Isabelle Huys
Targeted Oncology|January 18, 2012
Biosimilars and market access: a question of comparability and costs?Steven Simoens, Gilbert Verbeken, Isabelle Huys
Pageof 21